Capricor Therapeutics Inc (NASDAQ:CAPR)’s traded shares stood at 0.77 million during the last session, with the company’s beta value hitting 4.06.The CAPR share’s 52-week high remains $23.40, putting it -66.19% down since that peak but still an impressive 75.0% since price per share fell to its 52-week low of $3.52. The company has a valuation of $640.22M, with an average of 1.46 million shares in intraday trading volume over the past 10 days and average of 2.45 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Capricor Therapeutics Inc (CAPR), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give CAPR a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
The 5-day price performance for the stock is 9.15%, and -26.13% over 30 days. With these gigs, the year-to-date price performance is 187.93%. Short interest in Capricor Therapeutics Inc (NASDAQ:CAPR) saw shorts transact 4.41 million shares and set a 3.9 days time to cover.
The extremes give us $10 and $21.5 for target low and target high price respectively. As such, CAPR has been trading -52.7% off suggested target high and 28.98% from its likely low.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
Looking at statistics comparing Capricor Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Capricor Therapeutics Inc (CAPR) shares are 195.18% up over the last 6 months, with its year-to-date growth rate lower than industry average at -46.99% against 12.30%.
CAPR Dividends
Capricor Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders
Capricor Therapeutics Inc insiders hold 16.75% of total outstanding shares, with institutional holders owning 18.53% of the shares at 22.26% float percentage. In total, 18.53% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 1.63 million shares (or 5.194% of shares), all amounting to roughly $7.77 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 1.55 million shares, or about 4.9401% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $7.39 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Capricor Therapeutics Inc (CAPR) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 872.18 shares. This is just over 1.92% of the total shares, with a market valuation of $12.28 million. Data from the same date shows that the other fund manager holds a little less at 665.6, or 1.46% of the shares, all valued at about 9.37 million.
